NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7. In this research study we are: * Evaluating the safety and possible effectiveness of NPX372. * Identifying a safe and tolerable dose or doses for further study. Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Dose Limiting Toxicity (DLT)
Timeframe: From first dose through 21 days
Overall incidence of Dose Limiting Equivalent Toxicity (DLET) during treatment
Timeframe: From first dose up to 24 months
Incidence of AEs, characterized overall and by type, seriousness, relationship to NPX372, and severity.
Timeframe: From first dose up to 24 months
Number of participants with abnormal laboratory parameters, vital signs, electrocardiogram (ECG) parameters, physical examination findings as characterized by type, frequency, timing, relationship to NPX372, and severity
Timeframe: From first dose up to 24 months
Drug discontinuation, drug interruptions/delays and dose reductions due to treatment-related AEs
Timeframe: From first dose up to 24 months
Number of participants with AEs, DLTs (inclusive of DLETs), and PD changes within blood
Timeframe: From first dose up to 24 months